


Evidera Oncology Value Frameworks Tool

The requirement for evidence base to support “value” of drug has been growing with the increasing cost of cancer care. Generally, the term “value” measures outcomes for the monetary expenditure incurred by an institution/individual. The methods for assessing the value vary depending on the country, health system, disease, and indication. For oncology treatments, various value frameworks are available: National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Memorial Sloan Kettering Cancer Center (MSKCC), Institute for Clinical and Economic Review (ICER), and the Institute for Clinical and Economic Review.

Evidera has created a tool that allows the user to compare their product’s “value” across these various frameworks or create their own user-defined framework and criteria.


Our tool allows the user to:

- Compare the value of their product using existing value frameworks
- Consider criteria that may not be included in traditional cost-effectiveness analysis
- Predict value scenarios for different stakeholders, identifying evidence gaps
- Support pricing and reimbursement value story
- Appropriately position their products in the market landscape



Value framework potential uses

Evidera's oncology value frameworks tool has a number of potential uses across a product's lifecycle. In early development it can be used to test the target product profile (TPP) and the feasibility of positive HTA assessments. During launch and/or post-launch, it can test value messages and be used as a post-launch HEOR tool.



Features of value frameworks tool

EASE OF USE	<ul style="list-style-type: none">• All frameworks under one Microsoft Excel file• Customizable to any treatment or indication• Instructions, guidance, and definitions for analyst use• Consolidation of inputs across frameworks
AUTOMATION & STANDARDIZATION	<ul style="list-style-type: none">• Automation of calculations for each framework• Standardization of scoring algorithms across frameworks¹
RESULTS PRESENTATION	<ul style="list-style-type: none">• Presentation of results in comparable formats across frameworks (i.e., common outputs such as final score, cost-effectiveness, and pricing)• Allows identification of value drivers and meets maximum value potential
SENSITIVITY ANALYSIS	<ul style="list-style-type: none">• Allows testing TPP, Phase II, and/or Phase III trial data• Testing of various efficacy/safety scenarios• One-way sensitivity analysis included

For more information, or to receive a demo of Evidera's oncology value frameworks tool, please contact us at info@evidera.com.

1: E.g., NCCN scores 1–5 based on panel scoring. Tool has built in scoring thresholds which are validated periodically